Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPAVEHDI first-line treatment study for grade II acute graft-versus-host disease
2023-508614-41-00Phase 2Authorised
- Sponsor
- CHRU Nancy
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methoxsalen, prednisone and methylprednisolone in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by CHRU Nancy. Planned start Mar 2024; status: authorised.
02
Drugs
methoxsalenprednisonemethylprednisolone
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2023-508614-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508614-41-00.